10-Q: AIBiotics Therapies Q2 2026: Persistent Losses, Working Capital Deficit

AIBiotics Therapies, Inc. reported continued net losses and a significant working capital deficit for the quarter ended June 30, 2026, raising concerns about its going concern status.

Summary

• AIBiotics Therapies, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026.
• The company reported no revenue for the three and six months ended June 30, 2026.
• Net loss for the three months ended June 30, 2026, was $536,968, compared to $486,149 for the same period in 2025.
• Net loss for the six months ended June 30, 2026, was $955,073, compared to $1,077,546 for the same period in 2025.
• As of June 30, 2026, the company had a working capital deficit of $4,875,875.
• The company's ability to continue as a going concern is subject to substantial doubt.
• General and administrative expenses decreased by 13.3% for the six months ended June 30, 2026, compared to the prior year period, primarily due to a decrease in consulting fees and product development expenses.
• Cash and cash equivalents decreased to $233,427 as of June 30, 2026, from $255,940 as of December 31, 2025.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative sentiment due to the company's continued net losses, significant working capital deficit, and substantial doubt regarding its ability to continue as a going concern, despite some operational expense reductions.

Positives

• General and administrative expenses decreased by 13.3% for the six months ended June 30, 2026, compared to the prior year period, from $892,226 to $773,126.
• The decrease in general and administrative expenses was primarily attributable to a decrease in consulting fees of $37,644 and a decrease in product development expenses of $156,372.
• Other expense for the six months ended June 30, 2026, decreased by 3.0% compared to the same period in 2025, from $187,503 to $181,947, driven by lower interest expense.

Negatives

• No revenue was generated for the three and six months ended June 30, 2026.
• Net loss for the three months ended June 30, 2026, was $536,968.
• Net loss for the six months ended June 30, 2026, was $955,073.
• Total liabilities were $5,151,494 as of June 30, 2026, significantly exceeding total assets of $549,592.
• A working capital deficit of $4,875,875 existed as of June 30, 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern.
• Cash and cash equivalents decreased by $22,513 during the six months ended June 30, 2026.
• Intangible assets, net, decreased from $604,566 as of December 31, 2025, to $273,973 as of June 30, 2026, due to amortization.

Risks

• The company has generated no revenues, experienced negative operating cash flows, and incurred operating losses since inception, raising substantial doubt about its ability to continue as a going concern.
• Management expects to continue funding operations primarily through debt or equity issuance, with no assurance of success.
• The company's existence is dependent upon management's ability to develop profitable operations and raise capital.
• There is no assurance that management's actions will result in profitable operations or the resolution of liquidity problems.
• The company has no off-balance sheet arrangements.
• A material weakness in internal control over financial reporting was identified, leading to disclosure controls and procedures not being effective at a reasonable assurance level.

Future Outlook

The company plans to fund its operations with its cash on hand and additional financing, and is actively pursuing additional equity financing. Management is devoting substantially all of its efforts to developing the company's business and raising capital, but there can be no assurance of success in achieving profitable operations or resolving liquidity problems.

Management Comments

• Management expects the Company to continue to fund its operations primarily through the issuance of debt or equity.
• Management is devoting substantially all of its efforts to developing its business and raising capital and there can be no assurance that the Company's efforts will be successful.
• No assurance can be given that management's actions will result in profitable operations or the resolution of its liquidity problems.
• Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Industry Context

StockSavvy.ai notes that AIBiotics Therapies operates in a sector that often requires significant capital investment for research, development, and scaling. The lack of revenue and continued net losses are common in early-stage biotechnology or technology development companies, but the severity of the working capital deficit and going concern issues are critical indicators for investors.

Corporate Governance

Related Party Transactions

• Accrued expenses - related party: $951,000 as of June 30, 2026, related to the AIBiotics Consulting Agreement with the CEO.
• Notes payable - related party: $165,000 as of June 30, 2026, with interest at 1.75% compounded annually.
• AIBiotics Consulting Agreement with CEO Benjamin Kaplan for $24,000 monthly consulting fee ($288,000 annually).
• CEO is eligible for bonus compensation based on EBITDA milestones and market capitalization, none of which have been met as of June 30, 2026.
• CEO is eligible for stock grants upon closing a Significant Transaction (financing of at least $500,000 or acquisition of at least $1,000,000).
• Board compensation accrued: $342,000 as of June 30, 2026.

Stakeholder Impact

• Shareholders: Continued net losses and going concern issues may negatively impact share value and investor confidence. Dilution risk exists due to potential future equity financing.
• Creditors: The company's significant liabilities and working capital deficit raise concerns about its ability to meet its obligations.
• Employees: Uncertainty regarding the company's future could impact employee morale and retention.
• Management: Faces significant challenges in achieving profitability and securing necessary financing.

Next Steps

• Continue efforts to develop profitable operations.
• Actively pursue additional equity financing.
• Manage cash on hand and additional financing to fund operations.
• The company will adopt ASU 2024-03 in its annual report for the year ended December 31, 2026, requiring disaggregation of income statement expenses.

Key Dates

Recommendation

The company exhibits significant financial distress with no revenue, increasing net losses (for the quarter), a substantial working capital deficit, and a going concern warning. While operating expenses have seen some reduction, this is insufficient to offset the fundamental lack of revenue and ongoing cash burn. The high level of debt and accrued liabilities, coupled with the material weakness in internal controls, presents a high-risk investment profile.

Keywords

AIBiotics Therapies, Form 10-Q, Quarterly Report, Financial Statements, Net Loss, Working Capital Deficit, Going Concern, General and Administrative Expenses